Galectin Therapeutics Inc. (NASDAQ:GALT) shares were up 5.9% on Thursday . The stock traded as high as $2.06 and last traded at $1.98, with a volume of 120,394 shares traded. The stock had previously closed at $1.87.

GALT has been the subject of several research reports. Roth Capital initiated coverage on shares of Galectin Therapeutics in a research note on Friday, July 1st. They set a “buy” rating for the company. HC Wainwright reaffirmed a “buy” rating on shares of Galectin Therapeutics in a research note on Thursday, May 12th. Zacks Investment Research raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 19th. Finally, FBR & Co reaffirmed a “buy” rating and set a $12.00 price objective on shares of Galectin Therapeutics in a research note on Thursday, August 11th.

The stock’s 50 day moving average is $1.72 and its 200 day moving average is $1.48. The firm’s market capitalization is $58.56 million.

Galectin Therapeutics (NASDAQ:GALT) last issued its earnings results on Tuesday, August 9th. The company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.04. Equities analysts expect that Galectin Therapeutics Inc. will post ($0.89) earnings per share for the current year.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.